Triple agonist: difference between revisions
Diff·revision 15 → 16·08:13, 6 Jun 2025
Difference between revision 15 and revision 16 of Triple agonist. 7 lines changed; the page grew by 559 bytes.
| Revision 15 — 17:50, 13 May 2025 GlossaryGleb (talk) fix the amino-acid substitution — position 8, not position 2 3,428 bytes ±0 | Revision 16 — 08:13, 6 Jun 2025 DeadSpaceDot (talk) give the isoelectric point with the method it was determined by 3,987 bytes +559 | ||
|---|---|---|---|
| 27 | Long-term consequences of sustained heart-rate elevation are the question phase 3 exists to answer, and no answer is available yet. See [[TRIUMPH trial programme]].{{r|jastreboff2023}} | 27 | Long-term consequences of sustained heart-rate elevation are the question phase 3 exists to answer, and no answer is available yet. See [[TRIUMPH trial programme]].{{r|jastreboff2023}} |
| 28 | 28 | ||
| + | 29 | == Status == | |
| + | 30 | No triple agonist is approved anywhere. [[Retatrutide|Retatrutide]] is in phase 3; others are earlier.{{r|coskun2022}} | |
| + | 31 | ||
| + | 32 | Material sold under these names by research-chemical suppliers is unapproved and, having no marketed reference product, has no generally available [[Reference standard|reference standard]] for identity confirmation. See [[Research use only]].{{r|usp1503}} | |
| + | 33 | ||
| 29 | == References == | 34 | == References == |
| 30 | {{reflist}} | 35 | {{reflist}} |
| 31 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." ''Cell Metabolism'' 34(9):1234–1247 (2022). PMID 35985340.</ref> | 36 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." ''Cell Metabolism'' 34(9):1234–1247 (2022). PMID 35985340.</ref> |
| 32 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> | 37 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). PMID 37366315.</ref> |
| + | 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 33 | 39 | ||
| 34 | == See also == | 40 | == See also == |
| ⋮ | ⋮ | ||
| 37 | * [[Glucagon]] | 43 | * [[Glucagon]] |
| 38 | * [[Survodutide]] | 44 | * [[Survodutide]] |
| + | 45 | * [[TRIUMPH trial programme]] | |
| 39 | 46 | ||
| 40 | {{DEFAULTSORT:Triple agonist}} | 47 | {{DEFAULTSORT:Triple agonist}} |